8
Apr
2016

PfizerGan Unravels, Gilead Gets NASH Drug, & Verily Self-Dealing

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.